Product Description
PF-07612577, a combination of agents PF-06264006 [CTB] + PF-07338233 [AVP], is being developed by Pfizer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05554237?term=PF-07612577&draw=2&rank=1)
Mechanisms of Action: LACTB Inhbitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for PF-07612577](https://pryzm-maps.s3.us-west-2.amazonaws.com/1209current_maps.png)
Countries in Clinic: Belgium
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Pyelonephritis|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2023-507117-10-00 | P1 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis |
2024-01-16 |
|
C4691001 | P1 |
Completed |
Urinary Tract Infections |
2023-06-23 |
28% |
C4691001 | P1 |
Completed |
Urinary Tract Infections |
2023-06-23 |
28% |